FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Diana Eccles

Research Profile

Disorders

Physiology

Genes & Molecular Sequences

Procedures

Chemicals & Drugs

Concepts & Ideas

Pedigree

Geographic Areas

Occupations

Genetic Counseling

Living Beings

Heterozygote

Co-author Network

Publications

TOP 3
Chey Loveday; Antonis C Antoniou; Diana Eccles; D Gareth Evans; Martin Gore; Deborah Hughes; Emma Ramsay; Anthony Renwick; Elise Ruark; Sheila Seal; Katie Snape; Clare Turnbull; Margaret Warren-Perry; Rosa Maria Munoz Xicola; Nazneen Rahman
Germline RAD51C mutations confer susceptibility to ovarian cancer.
L Robertson; G Ross; S Seal; Susan Shanley; C Turnbull; A Tutt; M Warren-Perry; S Butler; Diana Eccles; D G R Evans; H Hanson; R Houlston; I Howell; D Hughes; N Rahman
BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.
D G R Evans; Anthony Howell; J L Jones; Fiona Lalloo; D Ward; Diana Eccles
Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Diana Eccles (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Chey Loveday; Antonis C Antoniou; Diana Eccles; D Gareth Evans; Martin Gore; Deborah Hughes; Emma Ramsay; Anthony Renwick; Elise Ruark; Sheila Seal; Katie Snape; Clare Turnbull; Margaret Warren-Perry; Rosa Maria Munoz Xicola; Nazneen Rahman
Germline RAD51C mutations confer susceptibility to ovarian cancer.
Nature genetics 2012;44(5):475-6; author reply 476.
2012: L Robertson; G Ross; S Seal; Susan Shanley; C Turnbull; A Tutt; M Warren-Perry; S Butler; Diana Eccles; D G R Evans; H Hanson; R Houlston; I Howell; D Hughes; N Rahman
BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.
British journal of cancer 2012;106(6):1234-8.
2011: D G R Evans; Anthony Howell; J L Jones; Fiona Lalloo; D Ward; Diana Eccles
Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer.
Journal of medical genetics 2011;48(8):520-2.
2011: Michela Raponi; Jana Kralovicova; Ellen Copson; Petr Divina; Diana Eccles; Peter Johnson; Diana Baralle; Igor Vorechovsky
Prediction of single-nucleotide substitutions that result in exon skipping: identification of a splicing silencer in BRCA1 exon 6.
Human mutation 2011;32(4):436-44.
2010: J R F Wilson; A C Bateman; H Hanson; Q An; G Evans; N Rahman; J L Jones; Diana Eccles
A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations.
Journal of medical genetics 2010;47(11):771-4.
2010: Clare Turnbull; Sarah Hines; Anthony Renwick; Deborah Hughes; David Pernet; Anna Elliott; Sheila Seal; Margaret Warren-Perry; D Gareth Evans; Diana Eccles; Michael R Stratton; Nazneen Rahman
Mutation and association analysis of GEN1 in breast cancer susceptibility.
Breast cancer research and treatment 2010;124(1):283-8.
2010: Clare Turnbull; Shahana Ahmed; Jonathan Morrison; David Pernet; Anthony Renwick; Mel Maranian; Sheila Seal; Maya Ghoussaini; Sarah Hines; Catherine S Healey; Deborah Hughes; Margaret Warren-Perry; William Tapper; Diana Eccles; D Gareth Evans; Maartje Hooning; Mieke Schutte; Ans van den Ouweland; Richard Houlston; Gillian Ross; Cordelia Langford; Paul D P Pharoah; Michael R Stratton; Alison M Dunning; Nazneen Rahman; Douglas F Easton
Genome-wide association study identifies five new breast cancer susceptibility loci.
Nature genetics 2010;42(6):504-7.
2009: Emma Edwards; Catharina Yearwood; Julie Sillibourne; Diana Baralle; Diana Eccles
Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer.
Familial cancer 2009;8(4):479-82.
2008: Antonis C Antoniou; R Hardy; L Walker; D G R Evans; Andrew Shenton; Rosalind Eeles; Susan Shanley; G Pichert; L Izatt; S Rose; F Douglas; Diana Eccles; P J Morrison; J Scott; Ron L Zimmern; Douglas F Easton; Paul D P Pharoah
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
Journal of medical genetics 2008;45(7):425-31.
2007: Claire Foster; M Watson; Rosalind Eeles; Diana Eccles; S Ashley; R Davidson; James Mackay; P J Morrison; Penelope Hopwood; D G R Evans
Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up.
British journal of cancer 2007;96(5):718-24.
2007: Nazneen Rahman; Sheila Seal; Deborah Thompson; Patrick Kelly; Anthony Renwick; Anna Elliott; Sarah Reid; Katarina Spanova; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Lesley McGuffog; Sandra Hanks; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.
Nature genetics 2007;39(2):165-7.
2006: Susan Shanley; Kate McReynolds; Audrey Ardern-Jones; Roger Ahern; Indrajit Fernando; John Yarnold; Gareth Evans; Diana Eccles; Shirley Hodgson; Sue Ashley; Linda Ashcroft; Andrew Tutt; Elizabeth Bancroft; Susan Short; Ian Smith; G P H Gui; Lester Barr; Andrew Baildam; Anthony Howell; Gavin Royle; Lori J Pierce; Douglas Easton; Rosalind Eeles
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(23):7033-8.
2006: Susan Shanley; Kate McReynolds; Audrey Ardern-Jones; Roger Ahern; Indrajit Fernando; John Yarnold; Gareth Evans; Diana Eccles; Shirley Hodgson; Sue Ashley; Linda Ashcroft; Andrew Tutt; Elizabeth Bancroft; Susan Short; G P H Gui; Lester Barr; Andrew Baildam; Anthony Howell; Gavin Royle; Lori J Pierce; Douglas Easton; Rosalind Eeles
Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(23):7025-32.
2006: Sheila Seal; Deborah Thompson; Anthony Renwick; Anna Elliott; Patrick Kelly; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Munaza Ahmed; Katarina Spanova; Bernard North; Lesley McGuffog; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton; Nazneen Rahman
Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.
Nature genetics 2006;38(11):1239-41.
2006: Anthony Renwick; Deborah Thompson; Sheila Seal; Patrick Kelly; Tasnim Chagtai; Munaza Ahmed; Bernard North; Hiran Jayatilake; Rita Barfoot; Katarina Spanova; Lesley McGuffog; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton; Nazneen Rahman
ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles.
Nature genetics 2006;38(8):873-5.
2006: Zsofia Kote-Jarai; Lucy Matthews; Ana Osorio; Susan Shanley; Ian Giddings; Francois Moreews; Imogen Locke; D Gareth Evans; Diana Eccles; Richard D Williams; Mark Girolami; Colin Campbell; Rosalind Eeles
Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(13):3896-901.
2006: Johanna Tommiska; Sheila Seal; Anthony Renwick; Rita Barfoot; Linda Baskcomb; Hiran Jayatilake; Jirina Bartkova; Jonna Tallila; Milja Kaare; Anitta Tamminen; Päivi Heikkilä; D Gareth Evans; Diana Eccles; Kristiina Aittomäki; Carl Blomqvist; Jiri Bartek; Michael R Stratton; Heli Nevanlinna; Nazneen Rahman
Evaluation of RAD50 in familial breast cancer predisposition.
International journal of cancer. Journal international du cancer 2006;118(11):2911-6.
2006: Nadine Andrieu; David E Goldgar; Douglas F Easton; Matti A Rookus; Richard Brohet; Antonis C Antoniou; Susan Peock; Gareth Evans; Diana Eccles; Fiona Douglas; Catherine Noguès; Marion Gauthier-Villars; Agnès Chompret; Flora E van Leeuwen; Irma Kluijt; Javier Benitez; Brita Arver; Edith Olah; Jenny Chang-Claude
Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS).
Journal of the National Cancer Institute 2006;98(8):535-44.
2006: Gillian Mitchell; Antonis C Antoniou; Ruth Warren; Susan Peock; Judith Brown; Russell Davies; Jenny Mattison; Margaret Cook; Iqbal Warsi; D G R Evans; Diana Eccles; Fiona Douglas; Joan Paterson; Shirley Hodgson; Louise Izatt; Trevor Cole; Lucy Burgess; Rosalind Eeles; Douglas F Easton
Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Cancer research 2006;66(3):1866-72.
2006: Ellen R Copson; Helen E White; Jeremy P Blaydes; David O Robinson; Peter WM Johnson; Diana Eccles
Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.
BMC cancer 2006;6():80.
2005: Diana Eccles; Gabriella Pichert
Familial non-BRCA1/BRCA2-associated breast cancer.
The lancet oncology 2005;6(9):705-11.
2005: David Stirling; D G R Evans; Gabriella Pichert; Andrew Shenton; Elaine N Kirk; Sylvia Rimmer; C Michael Steel; Sheila Lawson; R M Camille Busby-Earle; Jane Walker; Fiona Lalloo; Diana Eccles; Anneke Lucassen; M E M Porteous
Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5588-96.
2005: Khalid K Alharbi; Mohammed Aldahmesh; Emmanuel Spanakis; Lema Haddad; Ros A Whittall; Xiao-he Chen; Hamid Rassoulian; Matt J Smith; Julie Sillibourne; Nicola J Ball; Nikki J Graham; Patricia J Briggs; Iain A Simpson; David I W Phillips; Deborah A Lawlor; Shu Ye; Stephen E Humphries; Cyrus Cooper; George Davey Smith; Shah Ebrahim; Diana Eccles; Ian N M Day
Mutation scanning by meltMADGE: validations using BRCA1 and LDLR, and demonstration of the potential to identify severe, moderate, silent, rare, and paucimorphic mutations in the general population.
Genome research 2005;15(7):967-77.
2004: M Watson; C Foster; Rosalind Eeles; Diana Eccles; S Ashley; R Davidson; James Mackay; P J Morrison; Penelope Hopwood; D G R Evans
Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort.
British journal of cancer 2004;91(10):1787-94.
2004: David J Bunyan; Diana Eccles; Julie Sillibourne; E Wilkins; N Simon Thomas; J Shea-Simonds; P J Duncan; C E Curtis; David O Robinson; John F Harvey; Nicholas C P Cross
Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification.
British journal of cancer 2004;91(6):1155-9.
2004: andrew sharp; Gabriella Pichert; Anneke Lucassen; Diana Eccles
RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1.
Human mutation 2004;24(3):272.
2004: Penelope Hopwood; David Wonderling; M Watson; Ann Cull; Fiona Douglas; T Cole; Diana Eccles; J Gray; Victoria Murday; M Steel; J Burn; Klim McPherson
A randomised comparison of UK genetic risk counselling services for familial cancer: psychosocial outcomes.
British journal of cancer 2004;91(5):884-92.
2004: D G R Evans; Diana Eccles; N Rahman; K Young; M Bulman; E Amir; Andrew Shenton; Anthony Howell; Fiona Lalloo
A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.
Journal of medical genetics 2004;41(6):474-80.
2004: Francesca Pigatto; Adrian Bateman; D Bunyan; Paul Strike; Esta Wilkins; Claire Curtis; Philippa Duncan; Denzil May; Karen Nugent; Diana Eccles
Economic and Practical Factors in Diagnosing HNPCC Using Clinical Criteria, Immunohistochemistry and Microsatellite Instability Analysis.
Hereditary cancer in clinical practice 2004;2(4):175-84.
2004: C Foster; D G R Evans; Rosalind Eeles; Diana Eccles; S Ashley; L Brooks; Trevor Cole; J Cook; R Davidson; Helen Gregory; James Mackay; Patrick J Morrison; M Watson
Non-uptake of predictive genetic testing for BRCA1/2 among relatives of known carriers: attributes, cancer worry, and barriers to testing in a multicenter clinical cohort.
Genetic testing 2004;8(1):23-9.
2003: Sheila Seal; Rita Barfoot; Hiran Jayatilake; Paula Smith; Anthony Renwick; Linda Bascombe; Lesley McGuffog; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton; Nazneen Rahman
Evaluation of Fanconi Anemia genes in familial breast cancer predisposition.
Cancer research 2003;63(24):8596-9.
2003: Wendy Lim; Nicholas Hearle; B Shah; Victoria Murday; Shirley V Hodgson; Anneke Lucassen; Diana Eccles; Ian C Talbot; Kay Neale; A G Lim; John O'Donohue; A Donaldson; R C Macdonald; I D Young; M H Robinson; P W R Lee; B J Stoodley; Ian Tomlinson; D Alderson; A G Holbrook; S Vyas; E T Swarbrick; A A M Lewis; R K S Phillips; richard Houlston
Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome.
British journal of cancer 2003;89(2):308-13.
2003: Mieke Schutte; Sheila Seal; Rita Barfoot; Hanne Meijers-Heijboer; Marijke Wasielewski; D Gareth Evans; Diana Eccles; Carel Meijers; Frans Lohman; Jan G M Klijn; Ans M W van den Ouweland; P Andrew Futreal; Katherine L Nathanson; Barbara L Weber; Douglas F Easton; Michael R Stratton; Nazneen Rahman
Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.
American journal of human genetics 2003;72(4):1023-8.
2003: Richard S Camplejohn; Ruth Gilchrist; Douglas Easton; E McKenzie-Edwards; DM Barnes; Diana Eccles; Audrey Ardern-Jones; S V Hodgson; PM Duddy; Rosalind A Eeles
Apoptosis, ageing and cancer susceptibility.
British journal of cancer 2003;88(4):487-90.
2001: M G Coleman; AC Gough; David J Bunyan; D Braham; Diana Eccles; John Primrose
Minisatellite instability is found in colorectal tumours with mismatch repair deficiency.
British journal of cancer 2001;85(10):1486-91.
2001: Anneke Lucassen; Eila Watson; Diana Eccles
Evidence based case report: Advice about mammography for a young woman with a family history of breast cancer.
BMJ (Clinical research ed.) 2001;322(7293):1040-2.
2000: Nazneen Rahman; MD Teare; Sheila Seal; Helene Renard; J Mangion; C Cour; D Thompson; Yin Yao Shugart; Diana Eccles; Peter Devilee; H Meijers; Katherine L Nathanson; Susan L Neuhausen; B Weber; Jenny Chang-Claude; Douglas F Easton; David E Goldgar; Michael R Stratton
Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22.
Oncogene 2000;19(36):4170-3.
2000: Shirley V Hodgson; Neva E Haites; MA Caligo; Jenny Chang-Claude; Diana Eccles; G Evans; Pål Møller; P Morrison; C M Steel; D Stoppa-Lyonnet; H F A Vasen
A survey of the current clinical facilities for the management of familial cancer in Europe. European Union BIOMED II Demonstration Project: Familial Breast Cancer: audit of a new development in medical practice in European centres.
Journal of medical genetics 2000;37(8):605-7.
2000: Kelly Woodford-Richens; S Bevan; Michael Churchman; B Dowling; D Jones; C G Norbury; Shirley V Hodgson; D Desai; Kay Neale; R K S Phillips; J Young; B Leggett; M Dunlop; P Rozen; Charis Eng; D Markie; MA Rodriguez-Bigas; E Sheridan; T Iwama; Diana Eccles; G T Smith; J C Kim; K M Kim; Julian R Sampson; G Evans; S Tejpar; Walter F Bodmer; Ian P M Tomlinson; richard Houlston
Analysis of genetic and phenotypic heterogeneity in juvenile polyposis.
Gut 2000;46(5):656-60.
1999: Pål Møller; G Evans; Neva E Haites; H F A Vasen; Marta M Reis; Elaine Anderson; Jaran Apold; Shirley Hodgson; Diana Eccles; H Olsson; D Stoppa-Lyonnet; Jenny Chang-Claude; Patrick J Morrison; G Bevilacqua; Ketil Heimdal; Lovise Maehle; Fiona Lalloo; Helen Gregory; PE Preece; Ake Borg; NC Nevin; MA Caligo; C Michael Steel
Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer.
Disease markers 1999;15(1-3):207-11.
1999: Patrick J Morrison; C Michael Steel; H F A Vasen; Diana Eccles; D G R Evans; Pål Møller; Shirley Hodgson; D Stoppa-Lyonnet; Jenny Chang-Claude; MA Caligo; Edith Olah; Neva E Haites; NC Nevin
Insurance implications for individuals with a high risk of breast and ovarian cancer in Europe.
Disease markers 1999;15(1-3):159-65.
1999: D G R Evans; E Anderson; Fiona Lalloo; H F A Vasen; M Beckmann; Diana Eccles; Shirley Hodgson; Pål Møller; Jenny Chang-Claude; P Morrison; D Stoppa-Lyonnet; M Steel; Neva E Haites
Utilisation of prophylactic mastectomy in 10 European centres.
Disease markers 1999;15(1-3):148-51.
1999: M Steel; E Smyth; H F A Vasen; Diana Eccles; G Evans; Pål Møller; Shirley Hodgson; D Stoppa-Lyonnet; Jenny Chang-Claude; MA Caligo; P Morrison; Neva E Haites
Ethical, social and economic issues in familial breast cancer: a compilation of views from the E.C. Biomed II Demonstration Project.
Disease markers 1999;15(1-3):125-31.
1999: D Stoppa-Lyonnet; MA Caligo; Diana Eccles; D G R Evans; Neva E Haites; N S Hodgson; Pål Møller; Patrick J Morrison; C Michael Steel; H F A Vasen; Jenny Chang-Claude
Genetic testing for breast cancer predisposition in 1999: which molecular strategy and which family criteria?
Disease markers 1999;15(1-3):67-8.
1999: Jenny Chang-Claude; H Becher; MA Caligo; Diana Eccles; G Evans; Neva E Haites; Shirley Hodgson; Pål Møller; Bernhard H F Weber; D Stoppa-Lyonnet
Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer.
Disease markers 1999;15(1-3):53-65.
1999: Shirley Hodgson; BJ Milner; I Brown; G Bevilacqua; Jenny Chang-Claude; Diana Eccles; G Evans; Helen Gregory; Pål Møller; P Morrison; M Steel; D Stoppa-Lyonnet; H F A Vasen; Neva E Haites
Cancer genetics services in Europe.
Disease markers 1999;15(1-3):3-13.
1999: Yin Yao Shugart; C Cour; Helene Renard; G Lenoir; David E Goldgar; Dawn M Teare; Douglas Easton; Nazneen Rahman; R Gusterton; Sheila Seal; Rita Barfoot; Michael Stratton; J Mangion; T Peelen; Ans M W van den Ouweland; H Meijers; Peter Devilee; Diana Eccles; H Lynch; B Weber; D Stoppa-Lyonnet; Y J Bignon; Jenny Chang-Claude
Linkage analysis of 56 multiplex families excludes the Cowden disease gene PTEN as a major contributor to familial breast cancer.
Journal of medical genetics 1999;36(9):720-1.
1999: S Bevan; Kelly Woodford-Richens; P Rozen; Charis Eng; J Young; M Dunlop; Kay Neale; Robin Phillips; D Markie; MA Rodriguez-Bigas; B Leggett; E Sheridan; Shirley Hodgson; T Iwama; Diana Eccles; Walter Bodmer; richard Houlston; Ian Tomlinson
Screening SMAD1, SMAD2, SMAD3, and SMAD5 for germline mutations in juvenile polyposis syndrome.
Gut 1999;45(3):406-8.
1998: H F A Vasen; Neva E Haites; D G R Evans; C Michael Steel; Pål Møller; Shirley Hodgson; Diana Eccles; P Morrison; D Stoppa Lyonet; Jenny Chang-Claude; MA Caligo
Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group.
European journal of cancer (Oxford, England : 1990) 1998;34(12):1922-6.
1998: richard Houlston; S Bevan; A Williams; J Young; M Dunlop; P Rozen; Charis Eng; D Markie; Kelly Woodford-Richens; MA Rodriguez-Bigas; B Leggett; Kay Neale; Robin Phillips; E Sheridan; Shirley Hodgson; T Iwama; Diana Eccles; Walter Bodmer; Ian Tomlinson
Mutations in DPC4 (SMAD4) cause juvenile polyposis syndrome, but only account for a minority of cases.
Human molecular genetics 1998;7(12):1907-12.
1997: Deborah J Marsh; S Roth; Kathryn L Lunetta; Akseli Hemminki; Patricia Dahia; Pertti Sistonen; Z Zheng; S Caron; Nathalie J van Orsouw; Walter F Bodmer; SE Cottrell; Malcolm G Dunlop; Diana Eccles; Shirley V Hodgson; Heikki Järvinen; Ilmo Kellokumpu; D Markie; Kay Neale; Robin Phillips; P Rozen; Sapna Syngal; Jan Vijg; Ian P M Tomlinson; Lauri A Aaltonen; Charis Eng
Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome.
Cancer research 1997;57(22):5017-21.
1997: Diana Eccles; P W Lunt; Yvonne Wallis; M Griffiths; B Sandhu; S McKay; D Morton; J Shea-Simonds; F Macdonald
An unusually severe phenotype for familial adenomatous polyposis.
Archives of disease in childhood 1997;77(5):431-5.
1995: Hani Gabra; L Taylor; B B Cohen; A Lessels; Diana Eccles; R C F Leonard; John F Smyth; Michael Steel
Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours.
British journal of cancer 1995;72(2):367-75.
1994: D C Shields; A J Marlow; R S Houlston; Diana Eccles; Newton E Morton
Prediction of genetic risks from segregation analyses of morbid risks.
Human heredity 1994;44(1):52-5.
1993: B J Milner; L A Allan; Diana Eccles; Henry C Kitchener; R C Leonard; K F Kelly; David E Parkin; Neva E Haites
p53 mutation is a common genetic event in ovarian carcinoma.
Cancer research 1993;53(9):2128-32.
1993: G J Beattie; J E Roulston; Diana Eccles; J M Richardson; J Fisken; R C F Leonard
Alpha-fucosidase as a marker of genetic deletion in ovarian carcinoma.
Annals of clinical biochemistry 1993;30 ( Pt 2)():207-8.
1992: Diana Eccles; R S Houlston
Ovarian cancer family and prophylactic choices.
Journal of medical genetics 1992;29(12):928.
1992: Diana Eccles; S E Russell; Neva E Haites; R Atkinson; D W Bell; L Gruber; I Hickey; K Kelly; Henry C Kitchener; R Leonard
Early loss of heterozygosity on 17q in ovarian cancer. The Abe Ovarian Cancer Genetics Group.
Oncogene 1992;7(10):2069-72.
1992: Diana Eccles; L Gruber; M Stewart; C M Steel; R C F Leonard
Allele loss on chromosome 11p is associated with poor survival in ovarian cancer.
Disease markers 1992;10(2):95-9.
1992: Diana Eccles; Jeff Cummings; M E Stewart; M Nicolson; M A Cornbleet; R C F Leonard; John F Smyth
A phase I and pharmacology study of GR63178A, a water-soluble analogue of mitoquidone.
Cancer chemotherapy and pharmacology 1992;29(5):375-8.
1992: Diana Eccles; L Brett; Alistair Lessells; L Gruber; D Lane; C M Steel; R C F Leonard
Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma.
British journal of cancer 1992;65(1):40-4.
1991: M E O'Brien; Diana Eccles; S G Allen; G Knight; A Rodger; U Chetty; John F Smyth; R C F Leonard
Mitozantrone and prednimustine in the treatment of advanced breast cancer--a toxic regimen with low activity.
Cancer chemotherapy and pharmacology 1991;28(5):402-4.
1990: Diana Eccles; G Cranston; C M Steel; Y Nakamura; R C F Leonard
Allele losses on chromosome 17 in human epithelial ovarian carcinoma.
Oncogene 1990;5(10):1599-601.
1989: Diana Eccles; S G Allan; C T Sang; M A Cornbleet
Small cell carcinoma of the oesophagus: report of three cases and review of published cases.
Thorax 1989;44(9):749-50.